Zum Hauptinhalt springen
xMedica

NCT07159763ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza…

Phase 310.000 Teilnehmende gesucht211 Studienzentren6 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2025-09-08; recorded start 2025-09-25
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 3 other studies in this databaseCounted from the lead sponsor named in the record (Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA))
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 181 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEGA

A very large study, international in scope: 10,000 participants (target), run at 211 sites, across 6 countries.

How this score is built
  • Enrolment38/40

    10,000 participants (target)

  • Site count25/25

    181 sites

  • Country count7/15

    5 countries

  • Planned duration6/10

    Planned over about 20 months

  • Sponsor scale2/10

    Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) has led 4 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). The goal of this study is to learn whether MK-1406 (CD388) can help prevent the flu in people who are at higher risk of becoming seriously ill from influenza. Researchers want to find out if MK-1406 dosed at a single study visit can provide protection against influenza compared with placebo. The study will include adolescents and adults who may be more vulnerable to complications from influenza because of their age, health conditions, or weakened immune systems. Researchers will also evaluate the safety of MK-1406 and how well participants tolerate the study medicine.

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, and tolerability of MK-1406 (CD388) administered as a single dose via 3 subcutaneous (SC) injections in adult and adolescent participants who are at higher risk of developing complications from influenza.

Erkrankungen

  • Influenza

Eignung

Eignung
GeschlechtAlle
Alter12 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: Primary Stratum A (non-immunocompromised participants who have chronic stable medical conditions) and Primary Stratum B (participants who are immunocompromised either due to underlying disease or receipt of immunosuppressive medications) * Has negative rapid antigen tests for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prior to dosing at Day 1 * Weight is ≥ 40 kg Primary Stratum A only * Has a history of pulmonary disease * Has moderate to severe asthma, as defined by the Global Initiative for Asthma (GINA 2025) * Has existing cardiac disease * Has insulin-dependent diabetes * Has moderate renal impairment * Is ≥ 65 years of age at the time of randomization but does not meet any of the above criteria for Primary Stratum A, and is otherwise healthy Primary Stratum B only * Has a solid tumor diagnosis AND has received chemotherapy and/or immunotherapy within 1 year of screening * Has a diagnosis of a hematologic malignancy within 5 years of screening AND has received any chemotherapy or biologic therapy within 1 year of screening * Participants who have had a solid organ transplant (SOT) must satisfy all of the following: * Has received a kidney, liver, heart, or lung transplant more than 6 months prior to screening * Is currently receiving at least two immunosuppressive medications * Participants who have had a hematopoietic stem cell transplant (HSCT) must satisfy at least one of the following: * Has a history of hematopoietic stem cell transplantation (HSCT) (i.e., autologous, allogeneic, bone marrow, peripheral blood stem cell, tandem \[peripheral blood and marrow\]) within 1 year of screening * Has a history of non-autologous HSCT with graft-versus-host disease (GvHD) requiring active treatment with immunosuppressants (e.g., systemic corticosteroids ≥1 mg/kg at screening), regardless of the duration of time since HSCT * Is receiving immunosuppressive medicines * Has received chimeric antigen receptor-modified T-cell therapy * Has received B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab) within the 12 months prior to screening * Has a diagnosis of any primary immunodeficiency except immunoglobulin A (IgA) deficiency * Has advanced or untreated human immunodeficiency virus (HIV) infection Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Known or suspected allergy or history of anaphylaxis or other serious adverse reactions to zanamivir (following administration of inhaled or intravenous formulations), monoclonal antibody (mAbs (including Fc domains)), or any of the components of CD388 or placebo * Has an acute (time-limited) or febrile (temperature ≥ 38.0°C \[≥ 100.4°F\]) illness within 7 days prior to planned dosing on Day 1 * Has severe chronic kidney disease (CKD) or is receiving hemodialysis * Receipt within the past 30 days or 5 half-lives (whichever is longer) or anticipated receipt of any drug or other biologic agent (e.g., mAbs) administered for the prevention or treatment of influenza * Has a clinically significant bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder) or medical history of significant bleeding or bruising following intramuscular or subcutaneous (SC) injections or venipuncture * Has previously enrolled in this study (CD388.SQ.3.06)

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielPREVENTION
VerblindungQUADRUPLE (4)
Teilnahme10.000 Teilnehmende gesucht

Sponsor und Mitwirkende

  • Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Sponsor

Studienarme und Interventionen

  • MK-1406EXPERIMENTAL

    Participants will receive 450 milligrams (mg) dose of MK-1406 (CD388) by subcutaneous (SC) injection.

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive placebo by SC injection.

Interventionen

  • Kombinationsprodukt MK-1406

    MK-1406 liquid for injection administered subcutaneously (SC)

  • Kombinationsprodukt Placebo

    MK-1406 matched liquid for SC injection

Endpunkte

  1. Primärer Endpunkt

    Number of Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug

    Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of participants experiencing protocol-defined ILI occurring after administration of MK-1406 (CD388), with influenza infection confirmed by an RT-PCR+ result based on a NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.

    Zeitrahmen Up to approximately 24 weeks post dose

  2. Sekundärer Endpunkt

    Number of participants with ≥1 Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants with ≥1 AE will be assessed.

    Zeitrahmen Up to approximately Day 197

  3. Sekundärer Endpunkt

    Number of Participants Who Discontinued from the Study Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinued the study because of an AE will be assessed.

    Zeitrahmen Up to approximately Day 197

  4. Sekundärer Endpunkt

    Number of Participants with Injection Site Reactions (ISRs)

    Participants will complete the injection site reaction questionnaire in the eDiary Day 1 through Day 8 following the study intervention administration to assess for reactogenicity, based on the US Food and Drug Administration (FDA) toxicity grading scale used for vaccine trials. Injection site reactions are graded on a scale from 1 to 5 where Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe and Grade 4 is potentially life threatening. The injection-site reactions assessed are pain, tenderness, erythema/redness, and induration/swelling.

    Zeitrahmen Up to approximately Day 8 post dose

  5. Sekundärer Endpunkt

    Number of Stratum B Participants Experiencing Protocol-defined Influenza-like Illness (ILI) Occurring ≥7 Days after and up to 24 Weeks after Administration of Study Drug

    Protocol-defined ILI includes: 1) Influenza infection confirmed by a reverse transcriptase-polymerase chain reaction positive (RT-PCR +) result from nasopharyngeal (NP) swab assayed at a central laboratory AND 2) New onset or worsening of ≥ 2 respiratory symptoms (nasal congestion, sore throat, or cough) OR New onset or worsening of 1 respiratory symptom (nasal congestion, sore throat, or cough) AND new onset of ≥ 1 systemic symptom (headache, feeling feverish or chills, body aches/pains, or fatigue). Number of Stratum B ((immunocompromised participants) experiencing protocol-defined ILI occurring after administration of CD388, with influenza infection confirmed by an RT-PCR+ result based on an NP swab assayed at a central laboratory (first occurrence only), as compared to placebo will be assessed.

    Zeitrahmen Up to approximately 24 weeks post dose

  6. Sekundärer Endpunkt

    Number of Participants with All-cause Hospitalization within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza

    Hospitalizations are defined as an overnight admission in a hospital or similar acute care facility, including emergency rooms due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration. Number of participants with all-cause hospitalization within 30 days after the onset of symptomatic influenza will be assessed.

    Zeitrahmen Up to 30 days after onset of symptomatic laboratory-confirmed influenza

  7. Sekundärer Endpunkt

    Number of Participants with All-cause Mortality within 30 Days after the Onset of Symptomatic Laboratory-Confirmed Influenza

    Number of participants with mortality due to any cause within 30 days after the onset of symptomatic laboratory-confirmed influenza infection which occurred from ≥ 7 days after and up to 24 weeks after study intervention administration will be determined.

    Zeitrahmen Up to 30 days after onset of symptomatic laboratory-confirmed influenza

  8. Sekundärer Endpunkt

    Plasma Concentrations Following Administration of MK-1406 (CD388)

    Blood samples will be collected at multiple time points to assess the plasma concentrations of MK-1406.

    Zeitrahmen Day 1 (pre-dose), Day 29, and Day 197 post dose

  9. Sekundärer Endpunkt

    Number of Participants with Treatment Emergent Anti-Drug Antibodies (ADAs)

    The number of participants with confirmed anti MK-1406 antibodies post-baseline (i.e. treatment-emergent ADAs) will be determined via evaluation of blood samples collected at multiple time points.

    Zeitrahmen Day 1 (pre-dose), Day 29, and Day 197 post dose

  10. Sekundärer Endpunkt

    Number of Participants with Treatment Boosted ADAs

    The number of participants with an increase in ADA titer over an initial positive baseline titer (i.e., treatment-boosted ADAs) will be determined will be determined via evaluation of blood samples collected at multiple time points.

    Zeitrahmen Day 1 (pre-dose), Day 29, and Day 197 post dose

Daten

Daten
Startdatum25. September 2025 (tatsächlich)
Primärer Abschluss2. Juli 2027 (geschätzt)
Abschluss2. Juli 2027 (geschätzt)
Erstveröffentlichung8. September 2025 (tatsächlich)
Zuletzt aktualisiert17. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtNovember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

93 Studienzentren rekrutieren

Argentina

Argentina
EinrichtungStadtBundesland oder RegionStatus
CINME - Centro de Investigaciones Metabólicas ( Site 0007)Buenos AiresBuenos Aires F.D.Aktiv, rekrutiert nicht
Centro de Estudios Infectológicos S.A. ( Site 0002)CABABuenos AiresAktiv, rekrutiert nicht
Equipo Ciencia ( Site 0008)Ciudad Autonoma de Buenos AiresBuenos AiresAktiv, rekrutiert nicht
Sanatorio Mayo Privado S.A ( Site 0003)CórdobaCórdoba ProvinceAktiv, rekrutiert nicht
Centro Medico de Enfermedades Respiratorias ( Site 0005)FloridaBuenos AiresAktiv, rekrutiert nicht
Instituto del Buen Aire ( Site 0006)Santa FeAktiv, rekrutiert nicht

Australia

Australia
EinrichtungStadtBundesland oder RegionStatus
Emeritus Research ( Site 0106)BotanyNew South WalesAktiv, rekrutiert nicht
Core Research Group ( Site 0102)BrisbaneQueenslandAktiv, rekrutiert nicht
Emeritus Research ( Site 0101)CamberwellVictoriaAktiv, rekrutiert nicht
Australian Clinical Research Network ( Site 0103)MaroubraNew South WalesAktiv, rekrutiert nicht
The AIM Centre Hunter Diabetes Centre ( Site 0105)NewcastleNew South WalesAktiv, rekrutiert nicht
Momentum St Leonards ( Site 0107)St LeonardsNew South WalesAktiv, rekrutiert nicht
Momentum Clinical Research Taringa ( Site 0104)TaringaQueenslandAktiv, rekrutiert nicht

Japan

Japan
EinrichtungStadtBundesland oder RegionStatus
Takeuchi Hospital ( Site 0818)Arakawa CityTokyoRekrutiert
Ishikawa Prefectural Central Hospital ( Site 0814)KanazawaIshikawa-kenRekrutiert
Medical Corporation Chiyukai Shin Komonji Hospital ( Site 0820)KitakyushuFukuokaRekrutiert
National Hospital Organization Tokyo National Hospital ( Site 0802)KiyoseTokyoRekrutiert
National Hospital Organization Kumamoto Medical Center ( Site 0801)KumamotoRekrutiert
Jobu Hospital for Respiratory Diseases ( Site 0821)MaebashiGunmaRekrutiert
Maebashi Hirosegawa Clinic ( Site 0804)MaebashiGunmaRekrutiert
National Hospital Organization Tokyo Medical Center ( Site 0807)Meguro CityTokyoRekrutiert
Association of Healthcare Corporation Oyama East Clinic ( Site 0823)OyamaTochigiRekrutiert
NewHeart Watanabe Institute ( Site 0811)SuginamiTokyoRekrutiert

South Africa

South Africa
EinrichtungStadtBundesland oder RegionStatus
Josha Research ( Site 0216)BloemfonteinFree StateAktiv, rekrutiert nicht
Madibeng Centre for Research ( Site 0201)BritsNorth WestAktiv, rekrutiert nicht
TREAD Research ( Site 0206)Cape TownWestern CapeAktiv, rekrutiert nicht
TASK Applied Science - Headquarter ( Site 0211)Cape TownWestern CapeAktiv, rekrutiert nicht
Tiervlei Trial Centre ( Site 0204)Cape TownWestern CapeAktiv, rekrutiert nicht
Centre for the Aids Programme of Research in South Africa. CAPRISA ( Site 0220)DurbanKwaZulu-NatalAktiv, rekrutiert nicht
Synergy Biomed Research Institute ( Site 0218)East LondonEastern CapeAktiv, rekrutiert nicht
Ubuntu Clinical Research Center ( Site 0208)JohannesburgGautengAktiv, rekrutiert nicht
Helen Joseph Hospital-Clinical HIV Research Unit ( Site 0205)JohannesburgGautengAktiv, rekrutiert nicht
Qhakaza Mbokodo Research Clinic ( Site 0215)LadysmithKwaZulu-NatalAktiv, rekrutiert nicht
Newtown Clinical Research Centre ( Site 0207)NewtownGautengAktiv, rekrutiert nicht
Paarl Research Centre ( Site 0213)PaarlWestern CapeAktiv, rekrutiert nicht
Jose Pearson TB Hospital ( Site 0202)Port ElizabethEastern CapeAktiv, rekrutiert nicht
Global Clinical Trials ( Site 0212)PretoriaGautengAktiv, rekrutiert nicht
Emmed Research Incorporating ( Site 0209)PretoriaGautengAktiv, rekrutiert nicht
Jongaie Research ( Site 0214)Pretoria WestGautengAktiv, rekrutiert nicht
Aurum Institute - Rustenburg ( Site 0203)RustenburgNorth WestAktiv, rekrutiert nicht
Welkom Clinical Trial Centre ( Site 0219)WelkomFree StateAktiv, rekrutiert nicht

United Kingdom

United Kingdom
EinrichtungStadtBundesland oder RegionStatus
Aberdeen Royal Infirmary ( Site 0423)AberdeenAberdeen CityRekrutiert
Birmingham Heartlands Hospital ( Site 0440)BirminghamRekrutiert
Queen Elizabeth Hospital ( Site 0411)BirminghamAktiv, rekrutiert nicht
Layton Medical Centre ( Site 0405)BlackpoolLancashireRekrutiert
Bradford Royal Infirmary ( Site 0444)BradfordRekrutiert
Royal Sussex County Hospital ( Site 0443)BrightonBrighton And HoveRekrutiert
Southmead Hospital ( Site 0409)BristolBristol, City ofAktiv, rekrutiert nicht
Velocity Clinical Research, Bristol ( Site 0428)BristolBristol, City ofRekrutiert
University Hospital of Wales ( Site 0420)CardiffWalesAktiv, rekrutiert nicht

161 weitere Studienzentren sind im Registereintrag aufgeführt.

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 13. November 2026

    Abschlussdatum nach hinten verschoben

    Primary completion delayed 2 days

    2027-06-302027-07-02

  2. 6. November 2026

    Studienzentrum hinzugefügt

    26 sites added (211 total)

    185211

  3. 27. Oktober 2026

    Studienzentrum hinzugefügt

    4 sites added (185 total)

    181185

  4. 15. Oktober 2026

    Studienzentrum entfernt

    181 sites removed (181 total)

    362181

  5. 15. Oktober 2026

    Status geändert

    Status changed from Active not recruiting to Recruiting

    ACTIVE_NOT_RECRUITINGRECRUITING

  6. 15. Oktober 2026

    Rekrutierung eröffnet

    Recruitment opened

    ACTIVE_NOT_RECRUITINGRECRUITING

  7. 17. September 2026

    Abschlussdatum nach hinten verschoben

    Primary completion delayed 29 days

    2027-06-012027-06-30

  8. 17. September 2026

    Studienzentrum hinzugefügt

    181 sites added (362 total)

    181362